









Key Operational Measures	HY05	2005	Q106	Q206	HY06	Target 2006*
Organic revenue growth	2%	2%	1%	3%	2%	2-3%
Ordinary EBITA margin	15%	16%	13%	16%	15%	16.5-17
Cash conversion	57%	106%	65%	59%	55%	95-105
Key Financial Measures						
Free cash flow	€23 mln	€351 mln	€43 mln	€36 mln	€79 mln	± €350 m
ROIC %**	n/a	7%	n/a	n/a	n/a	7%
Diluted ordinary EPS	€0.45	€1.06	€0.22	€0.30	€0.52	€1.18-€1.















	20	03	20	04	20	05	2006		tal	
EUR Million	Original Target	Actual	Original Target	Actual	Original Target	Actual	Target	Original Target	Guida	
Product development spend	N/A	200	200 +50 (CC=235)	220	200 +70 (CC=255)	250	270	± 800 (incr. 200 3 yr period)	± 80 (incr. 3 yr perio	
Non-exceptional restructuring expenses	N/A	N/A	40	25	30	42	30	. 245	+ 26	
Exceptional restructuring expenses	100	96	40	44	10	20	-	± 215	± 215	± 20
FTE reductions	500	521	500	724	400	358	200	± 1600	± 180	
Total cost savings	20	29	40	70	80	100	120	100-110	150-1 run-ra	

EUR Million	Q105	Q205	HY05	FY05	Q106	Q206	HY06	FY06
Non-exceptional restructuring costs	9	7	16	42	6	8	14	30
Exceptional restructuring costs	3	4	7	20	-	-	-	
FTE reductions	83	98	181	358	47	10	57	200
Total cost savings	22	25	47	100	28	30	58	120





EUR Million	HY06	HY05	Actual Currencies %	Constant Currencies %	Organ Growt %
Revenues	1,770	1,580	12	9	2
Ordinary EBITA	262	242	9	5	(6)
Ordinary EBITA margin %	15	15			
EBITA margin %	15	15			
Ordinary Net Income	161	135	20	9	
Ordinary diluted EPS	€0.52	€0.45	18	6	
Free cash flow	79	23			

		10/05					
EUR Million	HY06	HY05			HY06	HY06 Ordina	
Revenue	1,770	1,580		EUR Million	Revenues	EBIT	
Ordinary EBITA	262	242		Health	384	41	
Ordinary EBITA margin %	15	15		CFS	267	54	
Exceptional restructuring	0	(7)		TAL	343	82	
EBITA	262	235		LTRE	651	90	
EBITA margin %	15	15		Education	125	11	
Amortization	(55)	(34)		Corporate		(16)	
Operating profit	207	201		Total	1,770	262	
Results on disposals	7	0	- 0				
Income from investments	3	3		perating Profit acrease of amor			
Financing results	(48)	(60)		inancing costs were lower than the si			
Profit before tax	169	144	■ F				
Income tax expense	(38)	(35)		eriod last year (
Profit for the period	131	109		he mix of matur			
Net results from associates	0	0	fı	rom derivatives	and currency	y results	
Net Income	131	109					

EUR Million	HY06	HY05
Net income attributable to equity holders	131	109
Amortization of intangibles	55	34
Taxation on amortization	(20)	(13)
Results on disposals (after tax)	(5)	0
Exceptional restructuring expense (after tax)	0	5
Ordinary Net Income	161	135
Ordinary diluted EPS	€0.52	€0.45
Weighted average number of shares	306	301
Weighted average diluted shares	321	314

EUR Million	June 06	Dec 05	June (
Total non-current assets	4,102	3,805	3,8
Total current assets	1,250	1,635	1,461
Total current liabilities	(2,701)	(2,562)	(1,941)
Working capital	(1,451)	(927)	(48)
Capital Employed	2,651	2,878	3,33
Total group equity	1,091	1,099	91
Total non-current liabilities	1,230	1,436	2,14
Deferred tax liabilities	137	80	
Employee benefits	178	250	24
Provisions	15	13	2
Total Financing	2,651	2,878	3,33

EUR Million	HY06	HY05	
Operating Profit	207	201	Increase in EBIT.
Amortization & Depreciation	100	78	amortization fro acquisitions, off
Exceptional restructuring expense	-	7	slight increase o
Autonomous movements in working capital	(124)	(109)	working capital compared to las
Cash Flow from Operations	183	177	Lower corporate
Paid Financing costs	(67)	(64)	due to a tax refu tax paid in prior
Paid corporate income tax	14	(38)	Cash corporate i
Appropriation of restructuring provisions	(20)	(23)	tax was therefor positive.
Share-based payments	9	6	
Other	0	2	
Cash Flow from Operating Activities	119	60	

EUR Million	HY06	HY05	
Cash Flow from Operating Activities	119	60	
Net capital expenditure on fixed assets	(40)	(38)	Higher acquisition
Net Acquisition spending	(433)	(282)	spending is largely to Healthcare Analy
Net receipts from disposal of activities	2	1	Provation and Heyr
Dividends received	0	1	Swap gains in 3rd qu
Cash from derivatives	1	30	Buy-back 1 million
Cash Flow from Investing Activities	(470)	(288)	2004 dividend was t
Exercise of share options	3	8	57% stock versus 52 over 2005
New loans / (redemptions)	138	(3)	0001 2003
Movement in bank overdrafts	(5)	46	
Repurchased shares	(19)	0	
Dividend payments	(80)	(69)	1
Cash Flow from Financing Activities	37	(18)	

Free Cash Flow			
EUR Million	HY06	HY05	
Cash flow from operating activities	119	60]
Cash flow from investments activities	(470)	(288)	
Cash flow from financing activities	37	(18)	
Net Cash Flow	(314)	(246)	
Cash and cash equivalents as at January 1	428	687	
Exchange differences on cash equivalents	0	6	
Cash and Cash Equivalents as at June 30	114	447	
Cash flow from operating activities	119	60	
Capital expenditure on fixed assets	(40)	(38)	1
Dividends received	0	1	1
Free Cash Flow	79	23	







2%	2-3%		
	Z-J/0		Improved growthMargin improvement
16%	16.5-17.0%		 Maintain working capital improvement
106%	95-105%	Y 1	Premium redemption convertible bond
			convertible bond
€351 mln	± €350 mln	Y	
7%	7%		Ordinary diluted EPS
€1.06	€1.18 - €1.23	\boldsymbol{r}	>10% increase
			including acquisition (€0.03 NDC)
			(€0.03 NDC)
	€351 mln 7%	€351 mln ± €350 mln 7% 7%	€351 mln ± €350 mln 7% 7%







2006 Outlook	& Beyo	nd: Rei	terated		
Key Operational Measures	2003	2004	2005	Target 2006*	2007*
Organic Revenue growth	-2%	1%	2%	2-3%	4%
Ordinary EBITA margin	18%	16%	16%	16.5%-17.0%	19-20%
Cash conversion	109%	126%	106%	95-105%	95-105%
Key Financial Measures					
Free cash flow	€393 mln	€456 mln	€351 mln	± €350 mln	≥ €400 ml
ROIC %**	7%	7%	7%	7%	≥ WACC**
Diluted ordinary EPS	€1.18	€1.02	€1.06	€1.18-€1.23	€1.45-€1.5
* At constant currencies EUR/USD 1.25 ** After Tax ***WACC is currently 8% after tax					
🗿 Wolters Kluwer		Q2	/HY 2006 Results	August 2, 2006 - Am	nsterdam 32





